COLYM Program
| Friday, October 6, 2023 | |
| Hall B |
|
| Lymphoma (COLYM) | |
| 09:15-10:45 | Session 1: What’s new in the field of lymphomas? Keynote lectures |
| Moderators: Stefano Luminari, Italy; Anna Sureda, Spain |
|
| Debate: Bringing genomics to the clinic in DLBCL: | |
| 09:15-09:35 | The pathologist point of view: Miguel Angel Piris, Spain |
| 09:35-09:55 | The clinician point of view: Andrew Davies, UK |
| 09:55-10:15 | Prognostic factors for cellular therapy strategies: Alberto Mussetti, Spain |
| 10:15-10:45 | Roundtable discussion: All session faculty |
| 10:45-11:15 | Coffee Break |
| 11:15-12:45 | Session 2: CLL and Richter’s syndrome |
| Moderators: Mehdi Hamadani, USA; Farrukh Awan, USA |
|
| 11:15-11:35 | Front line therapy in CLL: Time limited vs continuous: Farrukh Awan, USA |
| 11:35-11:55 | High risk CLL in the era of BTKi and BCL2 inhibitors: Is allo-HCT still a valid option? Mohamed Kharfan-Dabaja, USA |
| Debate: Best therapeutic option of Richter’s syndrome is: | |
| 11:55-12:05 | Novel agents: Farrukh Awan, USA |
| 12:05-12:15 | Allo-HCT: Alex Herrera, USA |
| 12:15-12:25 | CAR T cells: Sairah Ahmed, USA |
| 12:25-12:45 | Roundtable discussion: All session faculty |
| 12:45-13:15 | Lunch Box Pick-up and Break |
| COLYM Program Pause |
|
| 14:45-16:15 | Session 3: Follicular lymphoma |
| Moderators: Mohamed Kharfan-Dabaja, USA; Mehdi Hamadani, USA |
|
| Debate: Best option for treatment naïve FL patients is: | |
| 14:45-15:00 | Chemo free strategies: Julio Chavez, USA |
| 15:00-15:15 | R-chemo strategies: Pau Abrisqueta, Spain |
| Debate: Sequencing treatment in RR FL patients: | |
| 15:15-15:30 | Bispecific MoAb before CAR T cells are the SOC: Alex Herrera, USA |
| 15:30-15:45 | CAR T cells before bispecific MoAb are the SOC: Mazyar Shadman, USA |
| 15:45-16:15 | Roundtable discussion: All session faculty |
| 16:15-16:30 | Coffee Break |
| 16:30-18:00 | Session 4: Diffuse large B cell lymphomas |
| Moderators: Anna Sureda, Spain; Alex Herrera, USA |
|
| Debate: Is R-CHOP still the SOC for first-line therapy in DLBCL? | |
| 16:30-16:45 | Yes: Marek Trněný, Czech Republic |
| 16:45-17:00 | No: Hervé Tilly, France |
| Debate: Most feasible option for 3L therapy in DLBCL patients: | |
| 17:00-17:15 | CD19 autologous CAR T cells: Anna Sureda, Spain |
| 17:15-17:30 | CD20-CD3 bispecific monoclonal antibodies: Elly Lugtenburg, Netherlands |
| 17:30-18:00 | Roundtable discussion: All session faculty |
| Saturday, October 7, 2023 | |
| Hall B |
|
| Lymphoma (COLYM) | |
| 09:00-10:30 | Session 5: Peripheral T cell lymphomas |
| Moderators: Mohamed Kharfan-Dabaja, USA; Julio Chavez, USA |
|
| 09:00-09:15 | Insights in molecular pathology of PTCL: Laurence de Leval, Switzerland |
| Debate: PTCL NOS in CR1: | |
| 09:15-09:30 | SOC is watchful waiting: Eva Domingo-Doménech, Spain |
| 09:30-09:45 | SOC is auto-HCT: Graham Collins, UK |
| Debate: RR T cell NHL: | |
| 09:45-10:00 | Novel agents in R/R T cell lymphomas: Christopher Fox, UK |
| 10:00-10:15 | Allogeneic transplant in R/R T cell lymphomas: Mehdi Hamadani, USA |
| 10:15-10:30 | Roundtable discussion: All session faculty |
| 10:30-11:00 | Coffee Break |
| 11:00-12:30 | Session 6: Hodgkin’s lymhoma |
| Moderators: Stefano Luminari, Italy; Anna Sureda, Spain |
|
| 11:00-11:20 | The role of radiotherapy in 2023: Lena Specht, Denmark |
| 11:20-11:40 | What is the role for response-adapted first-line treatment strategies? Andrea Gallamini, France |
| 11:40-12:00 | Is HDT and autoHCT still SOC in the era of novel therapies? Ali Bazarbachi, Lebanon |
| 12:00-12:20 | When do I consider allogeneic HCT in cHL previously treated with BV and CKI? Miguel Perales, USA |
| 12:20-12:30 | Roundtable discussion: All session faculty |
| 12:30-13:00 | Lunch Box Pick-up and Break |
| COLYM Program Pause |
|
| 14:45-15:15 | COLYM Plenary Lecture |
| 14:45-15:05 | The latest in allogeneic CAR T: Miguel Perales, USA |
| 15:05-15:15 | Q&A |
| 15:15-16:15 | Session 7: Mantle cell lymphoma |
| Moderators: Christopher Fox, UK; Eva Domingo-Doménech, Spain |
|
| 15:15-15:30 | Front line consolidation with high-dose therapy and auto-HCT and post-transplant R maintenance: Should this approach be adandoned? Marek Trněný, Czech Republic |
| Debate: Best therapy for RR MCL is: |
|
| 15:30-15:45 | Cellular therapy: Alejandro Martín García-Sancho, Spain |
| 15:45-16:00 | BTKs: Wojciech Jurczak, Poland |
| 16:00-16:15 | Roundtable discussion: All session faculty |
| 16:15-16:30 | Coffee Break |
| 16:30-17:00 | IACH Closing Plenary Lecture in Hall A |